Idera Pharmaceuticals Presents Preclinical Data of Toll-Like Receptor Antagonists in Rheumatoid Arthritis Models
17 Juillet 2007 - 2:00PM
Business Wire
Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced the
presentation of preclinical data using its proprietary antagonists
of Toll-like receptors (TLR) 7 and 9 in mouse models of
collagen-induced arthritis (CIA), a commonly used model for
rheumatoid arthritis (RA). RA is an autoimmune disease
characterized primarily by Th1-like immune responses. The
presentation entitled �A Novel Class of DNA-Based TLR Antagonists
Ameliorates Collagen-Induced Arthritis in Mice� (Poster #52) was
made during the FASEB Summer Research Conference on Autoimmunity
being held in Saxtons River, VT, July 14-19, 2007. In the study,
TLR antagonist candidates, which block Th1-type cytokine induction
mediated through TLRs 7 and 9, were evaluated for their ability to
prevent the development of CIA in DBA/1 mice. Data from evaluation
of antagonist-treated mice showed dose-dependent suppression of
parameters of arthritis development, including arthritic swelling,
compared with untreated mice. In addition, microscopic examination
showed reduced inflammation in foot joints of the
antagonist-treated mice. These findings suggest that antagonists of
TLRs 7 and 9 may have a potential role in blocking Th1-type immune
responses, thereby inhibiting the progression of diseases such as
rheumatoid arthritis. �Idera�s chemistry-based drug discovery
platform has generated a number of novel TLR antagonist
candidates,� said Sudhir Agrawal, D. Phil., Chief Executive Officer
and Chief Scientific Officer. �Based on encouraging results of our
antagonist candidates in both CIA models and previously reported
lupus models, we plan to evaluate them in additional preclinical
models of autoimmune diseases. By inhibiting activation of immune
responses through specific TLRs, antagonists may have potential as
a future treatment option in autoimmune diseases.� About Idera
Pharmaceuticals, Inc. Idera Pharmaceuticals is a drug discovery and
development company that is developing drug candidates to treat
cancer and infectious, respiratory, and autoimmune diseases, and
for use as vaccine adjuvants. Idera�s proprietary drug candidates
are designed to modulate TLRs, the body�s first line of immune
defense. Idera�s pioneering DNA chemistry expertise enables it to
identify drug candidates for internal development and creates
opportunities for multiple collaborative alliances. Idera�s most
advanced clinical candidate, IMO-2055, is an agonist of TLR9 and is
currently in a Phase 2 trial in oncology and in a Phase 1/2
chemotherapy combination trial in oncology. Idera has selected a
second TLR9 agonist, IMO-2125, as a lead candidate for treating
infectious diseases. Idera is collaborating with Novartis
International Pharmaceutical, Ltd. for the discovery, development,
and commercialization of TLR9 agonists for the treatment of asthma
and allergy indications. Idera is also collaborating with Merck
& Co., Inc. for the use of Idera�s TLR7, 8 and 9 agonists in
combination with Merck�s therapeutic and prophylactic vaccines in
the areas of oncology, infectious diseases, and Alzheimer�s
disease. For more information, visit www.iderapharma.com. Forward
Looking Statements This press release contains forward-looking
statements concerning Idera Pharmaceuticals, Inc. that involve a
number of risks and uncertainties. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed to be forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"estimates," "intends," "should," "could," "will," "may," and
similar expressions are intended to identify forward-looking
statements. There are a number of important factors that could
cause Idera�s actual results to differ materially from those
indicated by such forward-looking statements, including whether
products based on Idera�s technology will advance into or through
the clinical trial process on a timely basis or at all and receive
approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether the Company will
complete enrollment of clinical trials or announce trial results in
the time expected; whether, if the Company�s products receive
approval, they will be successfully distributed and marketed;
whether the results of preclinical studies will be indicative of
results that may be obtained in clinical trials; whether the
Company�s collaborations with Novartis and Merck will be
successful; whether the patents and patent applications owned or
licensed by Idera will protect the Company�s technology and prevent
others from infringing it; whether Idera�s cash resources will be
sufficient to fund product development and clinical trials; and
such other important factors as are set forth under the caption
"Risk Factors" in Idera�s Quarterly Report on Form 10-Q filed on
May 14, 2007, which important factors are incorporated herein by
reference. Idera disclaims any intention or obligation to update
any forward-looking statements.
Idera Pharmaceutical (AMEX:IDP)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Idera Pharmaceutical (AMEX:IDP)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024